On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios

A well-known problem in spontaneous reporting systems (SRSs) for adverse drug reactions (ADRs) is under-reporting, that is, the problem that not all occurrences of ADRs are reported to the SRS. We look at the question of how to draw statistical conclusions from analyses of SRS data using reporting odds ratios. We will show that certain under-reporting problems play no role in assessing ADRs from SRSs: the results from the analyses turn out to be biased by some specific under-reporting problems, but not by others. SRS data can be particularly useful for the assessment of drug-drug interactions. If the assumption holds that there is an under-reporting problem for a first drug, and an under-reporting problem for a second drug, but that these two under-reporting problems do not influence each other, then reporting odds ratios estimated from SRSs are useful for signalling drug-drug interactions in the ADR-experiencing population. Similar results hold for covariate-drug interactions. We illustrate our results using two examples.

[1]  D. J. Finney,et al.  stematic Signalling of Adverse Reactions to Drugs , 1974, Methods of Information in Medicine.

[2]  B. Bégaud,et al.  Is reporting rate a good predictor of risks associated with drugs? , 1999, British journal of clinical pharmacology.

[3]  R. Meyboom,et al.  Non-puerperal lactation associated with antidepressant drug use. , 2003, British journal of clinical pharmacology.

[4]  F. Baudraz-Rosselet,et al.  Treatment of onychomycosis with terbinafine , 1992, The British journal of dermatology.

[5]  A. Egberts,et al.  Detecting drug–drug interactions using a database for spontaneous adverse drug reactions: an example with diuretics and non-steroidal anti-inflammatory drugs , 2000, European Journal of Clinical Pharmacology.

[6]  A. Agresti,et al.  Categorical Data Analysis , 1991, International Encyclopedia of Statistical Science.

[7]  M. D. B. Stephens,et al.  The detection of new adverse drug reactions , 1985 .

[8]  M. Praus,et al.  Alert systems for post-marketing surveillance of adverse drug reactions. , 1993, Statistics in medicine.

[9]  Rawlins,et al.  Attitudinal survey of voluntary reporting of adverse drug reactions. , 1999, British journal of clinical pharmacology.

[10]  W. O'Brien,et al.  Adverse reactions to nonsteroidal anti-inflammatory drugs. Diclofenac compared with other nonsteroidal anti-inflammatory drugs. , 1986, The American journal of medicine.

[11]  D. Grobbee,et al.  Adverse Cardiovascular Effects of NSAIDs in Patients with Congestive Heart Failure , 1997, Drug safety.

[12]  D. J. Finney,et al.  Statistical Logic in the Monitoring of Reactions to Therapeutic Drugs , 1971, Methods of Information in Medicine.

[13]  S J Evans,et al.  Pharmacovigilance: a science or fielding emergencies? , 2000, Statistics in medicine.

[14]  L. Wilton,et al.  Underreporting of suspected adverse drug reactions to newly marketed (“black triangle”) drugs in general practice: observational study , 1998, BMJ.

[15]  D. J. Finney,et al.  The detection of adverse reactions to therapeutic drugs. , 1982, Statistics in medicine.

[16]  B. Stricker,et al.  Serum sickness-like reactions to cefaclor. , 1992, Journal of clinical epidemiology.

[17]  J. Ottervanger,et al.  NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. , 1998, Archives of internal medicine.

[18]  R. Meyboom,et al.  Signalling possible drug-drug interactions in a spontaneous reporting system: delay of withdrawal bleeding during concomitant use of oral contraceptives and itraconazole. , 1999, British journal of clinical pharmacology.

[19]  William DuMouchel,et al.  Bayesian Data Mining in Large Frequency Tables, with an Application to the FDA Spontaneous Reporting System , 1999 .

[20]  Patrick C. Waller,et al.  Responding to drug safety issues , 1999, Pharmacoepidemiology and drug safety.

[21]  Y. Tsong,et al.  Comparing reporting rates of adverse events between drugs with adjustment for year of marketing and secular trends in total reporting. , 1995, Journal of biopharmaceutical statistics.